中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 35 Issue 2
Feb.  2019
Turn off MathJax
Article Contents

Changes in procoagulant and anticoagulant factors in patients with hepatitis B cirrhosis

DOI: 10.3969/j.issn.1001-5256.2019.02.020
Research funding:

 

  • Received Date: 2018-09-20
  • Published Date: 2019-02-20
  • Objective To investigate the changes in procoagulant and anticoagulant factors and routine coagulation markers in patients with hepatitis B cirrhosis and their clinical significance. Methods A total of 105 patients with hepatitis B cirrhosis who were admitted to Department of Infectious Diseases in The First Hospital of Lanzhou University from January 2017 to October 2018 were enrolled, and according to the Child-Pugh class, these patients were divided into group A ( 42 patients with Child-Pugh class A cirrhosis) , group B ( 39 patients with Child-Pugh class B cirrhosis) , and group C ( 24 patients with Child-Pugh class C cirrhosis) . Routine coagulation markers including prothrombin time ( PT) and activated partial prothrombin time ( APTT) , blood coagulation factors ( Ⅱ, Ⅴ, Ⅶ, Ⅷ, and Ⅺ) , anti-thrombin ( AT) , protein C ( PC) , and free protein S ( FPS) were measured for all patients. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups; a Spearman correlation analysis was also performed. Results There were significant differences in PT and APTT between the three groups ( F = 55. 11 and 12. 09, both P < 0. 001) ; group C had significantly higher PT and APTT than groups A and B, and group B had significantly higher PT and APTT than group A ( all P < 0. 05) . There were significant differences in the activities of blood coagulation factorsⅡ, Ⅴ, Ⅶ, and XI between the three groups ( F = 32. 52, 14. 77, 38. 88, and 9. 24, all P < 0. 001) ; group C had significantly lower activities of these coagulation factors than groups B and A, and group B had significantly lower activities than group A ( all P < 0. 05) . There was a significant difference in the activity of blood coagulation factor Ⅷ between the three groups ( F = 4. 44, P < 0. 05) ; group C had a significantly higher activity than groups A and B ( P < 0. 05) , while there was no significant difference between group A and group B ( P >0. 05) . There were significant differences in the activities of AT, PC, and FPS between the three groups ( F = 25. 90, 30. 46, and 15. 58, all P < 0. 001) ; group C had significantly lower activities than groups B and A, and group B had significantly lower activities than group A ( all P < 0. 05) . The correlation analysis showed that Child-Pugh class was negatively correlated with blood coagulation factors Ⅱ, Ⅴ, Ⅶ, and Ⅺ and anticoagulant factors PC, FPS, and AT ( r =-0. 687, -0. 460, -0. 706, -0. 426, -0. 723, -0. 646, and-0. 468, all P < 0. 001) , and Child-Pugh class had the strongest correlation with blood coagulation factors Ⅱ and Ⅶ and the anticoagulant factor PC.Blood coagulation factors II and Ⅶ were positively correlated with the anticoagulant factor PC ( r = 0. 851 and 0. 745, both P < 0. 001) .Conclusion Patients with hepatitis B cirrhosis have reductions in both procoagulant and anticoagulant factors, and there is a significant correlation between them. An unstable balance may form in the body, which is not considered a conventional hypocoagulable state.

     

  • loading
  • [1]TSOCHATZIS EA, SENZOLO M, GERMANI G, et al.Systematic review:Portal veinthrombosis in cirrhosis[J].Aliment Pharmacol Ther, 2010, 31 (3) :366-374.
    [2]LISMAN T, PORTE RJ.Rebalanced hemostasis in patients with liver disease:Evidence and clinical consequences[J].Blood, 2010, 116 (6) :878-885.
    [3]TRIPODI A, ANSTEE QM, SOGAARD KK, et al.Hypercoagulability in cirrhosis:Causes and consequences[J].J Thromb Haemost, 2011, 9 (9) :1713-1723.
    [4]AMBROSINO P, TARANTINO L, DI MINNO G, et al.The risk of venous thromboembolism in patients with cirrhosis.A systematic review and meta-analysis[J].Thromb Haemost, 2017, 117 (1) :139-148.
    [5]CHEN DF, XIONG J.Advances in mechanisms and treatment of portal vein thrombosis in patients with liver cirrhosis[J].JClin Hepatol, 2017, 33 (3) :451-453. (in Chinese) 陈东风, 熊吉.肝硬化门静脉血栓形成的机制与治疗进展[J].临床肝胆病杂志, 2017, 33 (3) :451-453.
    [6]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J].JClin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
    [7]FERRO D, ANGELICO F, CALDWELL SH, et al.Bleeding and thrombosis in cirrhotic patients:What really matters?[J].Dig Liver Dis, 2012, 44 (4) :275-279.
    [8]CARNEVALE R, RAPARELLI V, NOCELLA C, et al.Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells.Implications for hypercoagulability in cirrhosis[J].JHepatol, 2017, 67 (5) :950-956.
    [9]SHOVLIN CL, ANGUS G, MANNING RA, et al.Endothelial cell processing and alternatively spliced transcripts of factor VIII:Potential implications for coagulation cascades and pulmonary hypertension[J].PLo S One, 2010, 5 (5) :e9154.
    [10]IKURA Y, OSUGA T.Changing common sense:Anti-platelet/coagulation therapy against cirrhosis[J].World J Hepatol, 2015, 8 (13) :1730-1734.
    [11]TRIPODI A.Hemostasis abnormalities in chronic liver failure[M]//GINS P, KAMATH P, ARROYO V.Chronic liver failure.Clinical Gastroenterology.Humana Press, 2011:289-303.
    [12]BACCOUCHE H, LABIDI A, FEKIH M, et al.Haemostatic balance in cirrhosis[J].Blood Coagul Fibrinolysis, 2017, 28 (2) :139-144.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1814) PDF downloads(291) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return